BST 02
Alternative Names: BST-02Latest Information Update: 09 Aug 2024
At a glance
- Originator BioSyngen
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver cancer
- Preclinical Cholangiocarcinoma
Most Recent Events
- 04 Jul 2024 Phase-I clinical trials in Liver cancer (Late-stage disease, Inoperable/Unresectable, Recurrent, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT06526832)
- 01 Feb 2024 BST 02 receives Fast Track designation for Liver cancer [Parenteral] (Late-stage disease, Metastatic disease) in China
- 31 Jan 2024 Center for Drug Evaluation (CDE) of the China National Drug Administration approves clinical trial application for BST 02